Home-Based Chronic Kidney Disease (CKD) Care in Native American's of New Mexico- A Disruptive Innovation
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Chronic Kidney Diseases
- Sponsor
- University of New Mexico
- Enrollment
- 529
- Locations
- 1
- Primary Endpoint
- The Patient Activation Measure (PAM)
- Status
- Completed
- Last Updated
- last year
Overview
Brief Summary
People reach End Stage Renal Disease (ESRD) due to progressive chronic kidney disease (CKD). CKD is associated with increased risk for heart disease and death. The burden of chronic kidney disease is increased among minority populations compared to Caucasians. New Mexico American Indians are experiencing an epidemic of chronic kidney disease due primarily to the high rates of obesity and diabetes. The present study entitled Home-Based Kidney Care is designed to delay / reduce rates of ESRD by early interventions in CKD. Investigators propose to assess the safety and efficacy of conducting a full-scale study to determine if home based care delivered by a collaborative team composed of community health workers, the Albuquerque Area Indian Health Board and University of New Mexico faculty will decrease the risk for the development and the progression of CKD.
Detailed Description
Hypothesis: Specific Aim 1: Screen 600 participants from four different American Indian tribes in New Mexico to identify incident cases of CKD and identify participants for the proposed study of HBKC; Specific Aim 2: Conduct a 12 month study of HBKC among 240 Native Americans randomized in a 1:1 allocation to HBKC group versus Delayed Intervention (DI) group to demonstrate improvement in Patient Activation Measures (PAM) and adherence to treatment. We will demonstrate that CKD clinical risk profiles will improve with HBKC as compared to DI at 12 months and 4 months post intervention (16 months); Specific Aim 3: To demonstrate that HBKC will improve psychological factors that map onto important cultural variations in treatment efficacy and health outcomes. Specifically, we will show improvement in potential mediators (treatment engagement, self-efficacy, coping and increased knowledge) and moderators (stigma, and chronic stress, and depression) of health disparity and outcome. Study Outcomes: (1) The patient activation measures and adherence; (2) Changes in clinical phenotypes including Cr, UACR, A1c, body weight, BMI, fasting glucose, blood pressure (BP), plasma lipids, and inflammatory markers; (3) Changes in the quantitative traits such as diet and scores from a battery of mental-health, self-efficacy, and quality of life instruments. Health Impact: The active participation of New Mexico tribal leadership and the Albuquerque Area Indian Health Board, as well as the accessibility to native CHR personnel, render the outcomes that will be demonstrated by this proposal easily sustainable over the long term. If successful, this program has the potential to change best-practices for CKD progression and to reduce health disparities in a cost-effective and sustainable manner.
Investigators
Vallabh O Shah
Professor
University of New Mexico
Eligibility Criteria
Inclusion Criteria
- •(1) live in a household with 1 participant
- •(2) age 21 to 80 years
- •(3) negative pregnancy test in women of child-bearing potential
- •(4) diagnosed diabetics or HbA1c \>7
- •(5) BMI \>27 kg/m2 and UACR of \>/= 30
Exclusion Criteria
- •(1) life expectancy \< 1 year
- •(2) pregnancy or absence of reliable birth control in women of child-bearing potential
- •(3) malignancy except non-melanoma skin cancer
- •(4) blind
- •(5) ESRD and on dialysis
- •(6) kidney transplant recipient
- •(7) unwilling or unable to give informed consent.
Outcomes
Primary Outcomes
The Patient Activation Measure (PAM)
Time Frame: Baseline, 6 and 12 months
Assesses an individual's knowledge, skill, and confidence for managing one's health and healthcare. PAM total scores have a theoretical range from 0 to 100, with higher scores representing greater patient activation.
Secondary Outcomes
- HbA1c(Baseline. Change from baseline at 6 and 12 months)
- Blood Glucose Levels(Baseline. Change from baseline at 6 and 12 months)
- HDL(Baseline. Change from baseline at 6 and 12 months)
- LDL(Baseline. Change from baseline at 6 and 12 months)
- Creatinine(Baseline. Change from baseline at 6 and 12 months)
- SF12 Physical(Baseline. Change from baseline at 6 and 12 months)
- SF12 Mental(Baseline. Change from baseline at 6 and 12 months)